Order Article Reprints

Marisi G, Petracci E, Raimondi F, Faloppi L, Foschi FG, Lauletta G, Iavarone M, Canale M, Valgiusti M, Neri LM, et al. ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. Cancers. 2019; 11(7):1023. https://doi.org/10.3390/cancers11071023

Marisi, Giorgia, Elisabetta Petracci, Francesco Raimondi, Luca Faloppi, Francesco Giuseppe Foschi, Gianfranco Lauletta, Massimo Iavarone, Matteo Canale, Martina Valgiusti, Luca Maria Neri, and et al. 2019. "ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib" Cancers 11, no. 7: 1023. https://doi.org/10.3390/cancers11071023

Marisi, G., Petracci, E., Raimondi, F., Faloppi, L., Foschi, F. G., Lauletta, G., Iavarone, M., Canale, M., Valgiusti, M., Neri, L. M., Ulivi, P., Orsi, G., Rovesti, G., Vukotic, R., Conti, F., Cucchetti, A., Ercolani, G., Andrikou, K., Cascinu, S., ... Casadei-Gardini, A. (2019). ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. Cancers, 11(7), 1023. https://doi.org/10.3390/cancers11071023